Alantolactone Attenuates Renal Fibrosis via Inhibition of Transforming Growth Factor β/Smad3 Signaling Pathway

CONCLUSION: Alantolactone improves renal fibrosis by inhibiting the TGF-β/Smad3 signaling pathway in obstructive nephropathy. Thus, alantolactone is a potential therapeutic agent for chronic kidney disease.PMID:38173367 | PMC:PMC10850280 | DOI:10.4093/dmj.2022.0231

Source: Diabetes and Metabolism Journal - January 4, 2024 Category: Endocrinology Authors: Kyeong-Min Lee Yeo Jin Hwang Gwon-Soo Jung Source Type: research